Chemistry, structure and function of approved oligonucleotide therapeutics
Nucleic Acids Research · 11.04.2023 · 51 (6) · 2529-2573
DOI: 10.1093/nar/gkad067 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nucleic Acids Research, online erschienen am 07.03.2023. Verfasst von Martin Egli und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Center for Structural Biology, and Vanderbilt Ingram Cancer Center, Vanderbilt University, School of Medicine, Nashville,…. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense. Die Arbeit wurde bisher 895-mal zitiert (Crossref) und nennt 431 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Alnylam Pharmaceuticals.
Abstract (Originalsprache)
Eighteen nucleic acid therapeutics have been approved for treatment of various diseases in the last 25 years. Their modes of action include antisense oligonucleotides (ASOs), splice-switching oligonucleotides (SSOs), RNA interference (RNAi) and an RNA aptamer against a protein. Among the diseases targeted by this new class of drugs are homozygous familial hypercholesterolemia, spinal muscular atrophy, Duchenne muscular dystrophy, hereditary transthyretin-mediated amyloidosis, familial chylomicronemia syndrome, acute hepatic porphyria, and primary hyperoxaluria. Chemical modification of DNA and RNA was central to making drugs out of oligonucleotides. Oligonucleotide therapeutics brought to market thus far contain just a handful of first- and second-generation modifications, among them 2′-fluoro-RNA, 2′-O-methyl RNA and the phosphorothioates that were introduced over 50 years ago. Two other privileged chemistries are 2′-O-(2-methoxyethyl)-RNA (MOE) and the phosphorodiamidate morpholinos (PMO). Given their importance in imparting oligonucleotides with high target affinity, metabolic stability and favorable pharmacokinetic and -dynamic properties, this article provides a review of these chemistries and their use in nucleic acid therapeutics. Breakthroughs in lipid formulation and GalNAc conjugation of modified oligonucleotides have paved the way to efficient delivery and robust, long-lasting silencing of genes. This review provides an account of the state-of-the-art of targeted oligo delivery to hepatocytes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Center for Structural Biology, and Vanderbilt Ingram Cancer Center, Vanderbilt University, School of Medicine, Nashville, TN 37232-0146, USA.
- Alnylam Pharmaceuticals, 300 Third Street, Cambridge, MA 02142, USA.
ORCID-Profile: Martin Egli, Muthiah Manoharan
Förderung
- Alnylam Pharmaceuticals
Zitieren
APA
Egli, M., & Manoharan, M. (2023). Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Research, 51(6), 2529-2573. https://doi.org/10.1093/nar/gkad067
Vancouver
Egli M, Manoharan M. Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Research. 2023;51(6):2529-2573. doi:10.1093/nar/gkad067
BibTeX
@article{Egli2023,
author = {Egli, Martin and Manoharan, Muthiah},
title = {Chemistry, structure and function of approved oligonucleotide therapeutics},
journal = {Nucleic Acids Research},
year = {2023},
volume = {51},
number = {6},
pages = {2529--2573},
doi = {10.1093/nar/gkad067}
}
EUVIMED